Circulating cell-free tumor DNA (ctDNA) test is witnessing increasing adoption for monitoring treatment response and detecting cancer recurrence after therapy. It is a non-invasive method for detecting cancer biomarkers in body fluids. ctDNA has shown potential to improve screening, diagnosis and treatment outcomes for various cancers through liquid biopsy.
Market key trends:
The increasing adoption of ctDNA testing as a liquid biopsy technique for treatment monitoring is expected to fuel the market growth over the forecast period. ctDNA can detect residual and recurrent cancer at an early stage by identifying tumor-specific genetic alterations in blood of cancer patients. It offers a convenient alternative to repeated tissue biopsies and allows real-time tracking of tumor evolution in response to therapy. ctDNA analysis is being integrated in clinical management of various cancers like breast, lung and colon cancers to personalize treatment approach and improve clinical outcomes. Further research and widening applications of ctDNA across the cancer continuum is expected to bring more opportunities over the coming years.
Segment Analysis
The global circulating cell-free tumor DNA market is segmented into sample type and application. Within sample type, the plasma segment dominated in 2021 due to increasing demand for liquid biopsy as a minimally invasive procedure for cancer screening and diagnosis. Plasma offers a rich source of circulating cell-free tumor DNA, which enables reliable detection and characterization of tumor-specific genetic alterations.
Key Takeaways
The Global Circulating Cell-Free Tumor DNA Market Demand is expected to witness high growth over the forecast period of 2023 to 2030. The global Circulating Cell-Free Tumor DNA Market is estimated to be valued at US$ 6.1 Bn in 2023 and is expected to exhibit a CAGR of 6.4% over the forecast period 2023 to 2030.
Regional analysis: North America currently dominates the global circulating cell-free tumor DNA market and is expected to maintain its lead through 2030. This is attributed to advanced healthcare infrastructure, favorable reimbursement policies, and high acceptance of advanced cancer diagnostic tests. Asia Pacific is expected grow at the fastest pace during the forecast period driven by improving access to healthcare, rising healthcare spending, and growing awareness about early cancer detection.
Key players: Key players operating in the circulating cell-free tumor DNA market are BASF SE, Perstorp Holding AB, Chemoxy International Ltd., and Merck Group. BASF SE dominates the market and offers a wide range of solutions for circulating cell-free tumor DNA applications. Perstorp Holding AB has a strong presence in the pharmaceutical and chemicals industry and provides products for circulating cell-free tumor DNA analysis.
Explore more information on this topic, Please visit -
https://www.insightprobing.com/circulating-cell-free-tumor-dna-market-size-and-trends-analysis/
Explore more trending article on this topic -
Explore more trending article related this topic -
Comments
0 comment